The FDA, in a stark reversal, on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide, from its ...

Federal regulators shook up a rapidly growing pharmaceutical marketplace when they announced that tirzepatide, the active ingredient in Eli Lilly’s Mounjaro and Zepbound, was no longer in shortage ...

The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug compounders ...

PS makes wellness more accessible through real-life stories, first-person perspectives, and expert-backed information. Our ...

This lengthy study with the drug Mounjaro seems to point to even better success than they’d hoped. Eli Lilly, the mind behind ...

In recent years, the pharmaceutical manufacturer has seen dizzying growth in its pipeline for a wide range of diseases. And ...

Peptide companies' are creating knock-off versions of these drugs that have not been approved by the FDA and contain ...

Lilly has earmarked $200 million for the upgrade, a company spokesperson confirmed to Fierce Pharma. The new project will ...

Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a ...

Teva Pharmaceutical Industries will pay $450 to settle the Department of Justice's investigation into allegations of price fixing and misuse of funds for kickbacks. Other pharmaceutical news reports ...

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

A voguish — and often daunting — problem can plague people who have experienced recent and relatively rapid weight loss.